Novogen
Ltd. (Nasdaq: NVGN) subsidiary CanTx and Yale University announced positive
pre-clinical data for its anti-cancer drug Cantrixil sending the stock price soaring $1.60 to close at $9.23.
Positive trial results for Novogen
April 20, 2015 at 17:02 PM EDT
